BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

10812	Companies
234240	Keywords
163037	Articles
125255	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 10/21/2025 at 09:05, 9 months 17 days ago

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
BioNxt Solutions Inc. announces a large-mass animal bioequivalence study for sublingual Cladribine formulation, targeting multiple sclerosis treatment, to optimize dosage parameters for upcoming human study

BioNxt Solutions Inc. Multiple Sclerosis Treatment Bioequivalence Study Drug Delivery Technologies Sublingual Cladribine Formulation
BRIEF

published on 10/10/2025 at 01:55, 9 months 29 days ago

BioNxt Solutions aborde le vote de l'assemblée générale annuelle en pleine grève postale

Assemblée Générale Annuelle Vote Campagne De Marketing Grève De Postes Canada Soumission Par Procuration
BRIEF

published on 10/10/2025 at 01:55, 9 months 29 days ago

BioNxt Solutions Addresses AGM Voting Amid Postal Strike

AGM Voting Marketing Campaign Canada Post Strike Proxy Submission
PRESS RELEASE

published on 10/10/2025 at 01:50, 9 months 29 days ago

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
BioNxt Solutions Inc. provides alternative voting options for shareholders due to Canada Post mail strike. Annual general meeting details and proxy voting instructions shared

Annual General Meeting Shareholders BioNxt Solutions Inc. Proxy Voting Voting Options
BRIEF

published on 10/09/2025 at 09:10, 9 months 29 days ago

BioNxt Completes Fast-Track Patent Filing for MS Treatment

Multiple Sclerosis Cladribine Patent Filing BioNxt Solutions Sublingual Delivery
BRIEF

published on 10/09/2025 at 09:10, 9 months 29 days ago

BioNxt finalise le dépôt accéléré d'un brevet pour le traitement de la sclérose en plaques

Sclérose En Plaques Cladribine Dépôt De Brevet Solutions BioNxt Administration Sublinguale
PRESS RELEASE

published on 10/09/2025 at 09:05, 9 months 29 days ago

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
BioNxt Solutions Inc. completes Track One priority patent filing with USPTO for sublingual thin-film cladribine formulation (BNT23001) targeting MS & other autoimmune diseases. Strategic move to strengthen IP position & advance regulatory approvals

BioNxt Solutions Inc. Multiple Sclerosis Patent Filing Sublingual Thin-Film Cladribine Formulation
BRIEF

published on 10/02/2025 at 09:10, 10 months 5 days ago

BioNxt Advances Targeted Chemotherapy Drug Delivery Platform

Biopharmaceutical Drug Delivery Research Advancements BioNxt Solutions Targeted Chemotherapy
BRIEF

published on 10/02/2025 at 09:10, 10 months 5 days ago

BioNxt développe une plateforme d'administration ciblée de médicaments de chimiothérapie

Biopharmaceutique Solutions BioNxt Administration De Médicaments Chimiothérapie Ciblée Avancées De La Recherche
PRESS RELEASE

published on 10/02/2025 at 09:05, 10 months 5 days ago

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
BioNxt Solutions Inc. reports significant advancement in targeted chemotherapy delivery platform and upcoming definitive agreement. Proprietary technology aims at 10-fold increase in therapeutic effect while safeguarding healthy cells

BioNxt Solutions Inc. Oncology Treatments Chemotherapy Delivery Platform Targeted Drug Delivery System Therapeutic Effect

Accesswire

Published on 08/08/2026 at 00:00, 3 hours 43 minutes ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 4 hours 28 minutes ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 4 hours 43 minutes ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 5 hours 13 minutes ago

UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 5 hours 28 minutes ago

Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services

View all ACCESSWIRE

EQS Group

Published on 08/07/2026 at 23:21, 4 hours 22 minutes ago

EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 8 hours 13 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 8 hours 28 minutes ago

ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 9 hours 33 minutes ago

Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:00, 9 hours 43 minutes ago

E-PANGO: Composition du capital au 31 juillet 2026

Les Echos

Published on 08/07/2026 at 18:54, 8 hours 49 minutes ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 8 hours 49 minutes ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 9 hours 3 minutes ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 9 hours 3 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 9 hours 43 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026

View all LES ECHOS COMFI WIRE